Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules by Leach, Amanda J. et al.
Leach et al. BMC Pediatrics 2014, 14:200
http://www.biomedcentral.com/1471-2431/14/200RESEARCH ARTICLE Open AccessOtitis media in children vaccinated during
consecutive 7-valent or 10-valent pneumococcal
conjugate vaccination schedules
Amanda Jane Leach1*, Christine Wigger1, Ross Andrews1, Mark Chatfield1, Heidi Smith-Vaughan1
and Peter Stanley Morris1,2Abstract
Background: In 2001 when 7-valent pneumococcal conjugate vaccine (PCV7) was introduced, almost all (90%)
young Australian Indigenous children living in remote communities had some form of otitis media (OM), including
24% with tympanic membrane perforation (TMP). In late 2009, the Northern Territory childhood vaccination schedule
replaced PCV7 with 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10).
Methods: We conducted regular surveillance of all forms of OM in children in remote Indigenous communities
between September 2008 and December 2012. This analysis compares children less than 36 months of age who
received a primary course of at least two doses of PCV7 or PHiD-CV10, and not more than one dose of another
pneumococcal vaccine.
Results: Mean ages of 444 PCV7- and 451 PHiD-CV10-vaccinated children were 20 and 18 months, respectively.
Bilaterally normal middle ears were detected in 7% and 9% respectively. OM with effusion was diagnosed in 41% and
51% (Risk Difference 10% [95% Confidence Interval 3 to 17] p = 0.002), any suppurative OM (acute OM or any TMP) in
51% versus 39% (RD −12% [95% CI −19 to −5] p = 0.0004], and TMP in 17% versus 14% (RD −3% [95% CI −8 to 2]
p = 0.2), respectively. Multivariate analyses described a similar independent negative association between suppurative OM
and PHiD-CV10 compared to PCV7 (Odds Ratio = 0.6 [95% CI 0.4 to 0.8] p = 0.001). Additional children in the household
were a risk factor for OM (OR = 2.4 [95% CI 2 to 4] p = 0.001 for the third additional child), and older age and male
gender were associated with less disease. Other measured risk factors were non-significant. Similar clinical results were
found for children who had received non-mixed PCV schedules.
Conclusions: Otitis media remains a significant health and social issue for Australian Indigenous children despite PCV
vaccination. Around 90% of young children have some form of OM. Children vaccinated in with PHiD-CV10 had less
suppurative OM than children vaccinated with PCV7. Ongoing surveillance during the PCV13 era, and trials of early
intervention including earlier and mixed vaccine schedules are warranted.
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Community based surveillance pre- and post- introduction
of seven-valent pneumococcal conjugate vaccine (PCV7)
indicates that less than 10% of Australian Indigenous
children living in remote Northern Territory (NT) com-
munities have normal middle ears and around 20% have* Correspondence: Amanda.leach@menzies.edu.au
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unless otherwise stated.tympanic membrane perforation, TMP (either acute
otitis media with perforation (AOMwiP), dry perforation
(DP), or chronic suppurative otitis media (CSOM)) [1,2].
Streptococcus pneumoniae (pneumococcus) and non-
typeable H. influenzae (NTHi) are major pathogens
detected by culture [2,3] or PCR [4] in ear discharge
of children with AOMwiP or CSOM. PCV7 has greatly
reduced vaccine-serotype invasive pneumococcal disease
(IPD) and has indirect protective effects via reduced
carriage [5]. Replacement by non-vaccine serotypes [6]td. This is an Open Access article distributed under the terms of the Creative
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addition to protection from three additional serotypes,
clinical trial data suggested that the 10-valent pneumococ-
cal Haemophilus influenzae protein D conjugate vaccine
(PHiD-CV10) may protect against NTHi otitis media
[8], although Australian regulatory authorities have not
approved a license indication for the latter [9]. The NT
infant vaccination schedule changed from a combination
PCV7/PPV23 to a 3 + 1 PHiD-CV10 schedule (Table 1).
Through ongoing surveillance of otitis media over this
period, we were able to compare the community level
impact of PCV schedule on OM and explore potential
associations between OM severity and risk factors. Our
primary hypotheses were that in children 6 months to
36 months of age the prevalence of TMP (AOMwiP, DP
and CSOM) would be less, and the prevalence of bilateral
normal middle ears would be higher in PHiD-CV10 vacci-
nated children compared to PCV7 vaccinated children.
Methods
Study design, setting, community recruitment and ethical
approval
Since 2001 a total of thirty five remote communities in
the NT [6] and one in Western Australia have participated
in at least one community-based cross sectional survey
of otitis media and nasopharyngeal carriage. This report
includes cross sectional data from 25 communities
participating between September 2008 and December
2012. The study was approved by the Human Research
Ethics Committee of the Northern Territory Department
of Health and the Menzies School of Health Research
(EC00153), and the Western Australian Aboriginal Health
Information and Ethics Committee (WAAHIEC). Each
community council provided written approval of the study
to the Ethics committee. Our research has adhered to
the STROBE guidelines as outlined at http://www.strobe-
statement.org.
Participant recruitment and consent
In these remote communities where the birth cohort is
between 5 and 45 infants per year, we aimed primarily to
see all children under 36 months of age as well as older
children (up to 6 years of age) if available. No random
selection methods were used. Individual families were
approached with information about the study. ConsentTable 1 Pneumococcal vaccines in the childhood
vaccination schedule for Northern Territory Indigenous
children
Date commenced Vaccine Age (mo)
1st July 2001 PCV7 & PPV23 2,4,6 18
1st October 2009* PHiD-CV10 2,4,6,18
1st October 2011 PCV13 2,4,6,18
*No other Australian jurisdiction recommended that PHiD-CV10 replace PCV7.was sought from parents for their child (regardless of ear
health status or history) to have an ear examination, nasal
swab, swab of ear discharge if present, and general child
health check. Parents or carers were also asked for permis-
sion to access the mother’s and the child’s medical records
and complete a lifestyle interview regarding information on
likely risk or protective factors for otitis media.
Inclusion and exclusion criteria
Aboriginal children between 0 and 6 years of age, resident
in participating communities, and whose parents or carers
provided signed consent, were eligible for surveillance.
For this report we limit analysis as described below (Statis-
tical analysis).
Clinical assessments
Ear examinations and general health assessments
All clinical assessments were made by ear health research
nurses with extensive training in the diagnosis and manage-
ment of otitis media in this population. Otoscopic findings
were recorded on a standardized form. Assessments were
made using a tympanometer (Grason Stadler GSI 38), a
LumiView (Welch Allyn) with Siegel’s speculum for
pneumatic otoscopy, and a video-otoscope (Welch Allyn
macroview or MedRx video-otoscopes).
General health measures
Common conditions of childhood were recorded at the
time of ear assessment by direct observation; the child’s
skin (head, arms, legs and trunk) was examined for the
presence of scabies, tinea, skin sores or other skin condi-
tion; presence of nasal discharge (visible at a distance of 1
meter), and any cough (spontaneous or cough on request,
either wet or dry). We categorised ‘not sure’ as absent.
Antibiotics and other treatments or referrals were provided
to participants according to local guidelines.
Definitions of OM
We categorized middle ear states as follows: (1) normal;
(2) otitis media with effusion (OME); (3) acute otitis
media without perforation (AOMwoP); (4) AOM with
perforation (AOMwiP); (5) dry perforation; and (6) chronic
suppurative otitis media (CSOM). The final middle ear
diagnosis reflected the child’s more severely affected ear
(highest category). We based our criteria for diagnosis
on recommendations for clinical practice in this popu-
lation [10]: (i) OME – intact and non-bulging tympanic
membrane (TM) and Type B tympanogram; (ii) AOM-
woP – any bulging of the TM and Type B tympanogram;
(iii) AOMwiP – middle ear discharge observed and TM
perforation recently healed or present for less than six
weeks or covering less than 2% of the pars tensa of the
TM; (iv) dry perforation – TM perforation without any
discharge observed; (v) CSOM – middle ear discharge
Table 2 Number of doses of pneumococcal vaccine
received by 444 PCV7 children, 451 PHiD-CV10 children
Doses
of PCV7
Doses of PHiD-CV10
0 1 2 3 4 TOTAL
0 33e 18 e 50 284 77 411
1 5 e 2 e 23 16 1 40
2 28 15 30 e 43
3 322 73 1 e 395¥
4 5 1 6
+ PPV23§ 138§
+ PCV13¥ 2¥ 0 19¥ 70¥ 1¥ 92¥
TOTAL 355 89 73 300 78 895
PCV7, 7-valent pneumococcal conjugate vaccine.
PHiD-CV10, 10-valent pneumococcal Haemophilus influenzae protein D
conjugate vaccine.
PCV13, 13-valent pneumococcal conjugate vaccine.
Included mixed schedules:
§138 children also received one dose PPV23: (ceased in October 2010) 138 of
177 PCV7 3-dose children who were age-eligible for PPV23.
¥92 children also received one dose PCV13:
2 of 322 PCV7 3-dose children.
19 of 50 PHiD-CV10 2-dose children.
70 of 284 PHiD-CV10 3-dose children.
1 of 77 PHiD-CV10 4-dose child.
Excluded schedules
e91 children were excluded, including two additional children (not shown in
Table 2) who received two doses of PHiD-CV10 and two doses of PCV13.
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weeks and covering at least 2% of the pars tensa of the
TM. We also include combination categories of any
suppurative OM (any AOM, AOMwiP or CSOM) and
any TMP (any AOMwiP, dry perforation or CSOM).
Where duration of discharge was not known, size of
perforation was used to distinguish AOMwiP and CSOM.
Where otosocopy was not successful we used the child’s
tympanometry result and defined the child’s status as
OME if either ear had a Type B tympanogram. We asked
the mother if she thought her child had ear pain that day
or during the previous evening. These a priori diagnostic
criteria have been applied in all our surveillance and clin-
ical trials conducted in this population since 2001 [1].
Medical record review
The child’s medical records were reviewed to obtain dates
of vaccinations, recent clinic presentations, antibiotics pre-
scribed within the previous 5 weeks, sex, gestational age,
date of birth, birth weight, and latest haemoglobin result.
Risk factor questionnaires
The parent or guardian (usually the mother) was asked a
standardised set of questions about common risk factors
for OM, including the number of siblings, numbers of
people and children (less than 5 years of age) living in
the child’s house, whether the mother or child’s siblings
had ever had TMP (“runny ears”), her highest level of
education, if she smoked, and whether the child was
exposed to campfire smoke within the previous week, the
number of days per week that the child attended child
care, whether the child washed with soap the previous
day, had ever used a pacifier, or was ever breastfed.
Statistical analysis
We compared children who had received at least 2 doses
of PCV7 with children who had received at least 2 doses
of PHiD-CV10 as their primary course vaccines, with or
without a subsequent single dose of an alternative PCV,
or PPV23. For this analysis we included children 0 to
36 months of age.
Confidence intervals (CI, 95%) and risk differences (RD,
95% CI) were calculated where appropriate. Stata version
12 was used for all data analyses [11].
Multivariate logistic regression adjusting for community
was undertaken to examine risk factors, including vaccine
type, for our combination category of any suppurative OM.
For comparisons of children with and without any suppura-
tive OM, children with dry perforation were excluded. A
global test was performed for categorical risk factors.
Missing data
If participants declined a clinical assessment or a swab,
the data were coded as missing. If parents or carersrefused or were unsure of their response to an interview
question, we also coded this as missing. Missing data
were then excluded from the denominator for summary
statistics.
Results
Participant exclusions and PCV vaccination status
We enrolled 1,027 children and made 1,088 child visits.
Only the first visit per child is included in this analysis.
Forty one children had received PCV13 only. We excluded
a further 91 children on the basis of their vaccination
status; 33 children who had not been vaccinated, 25
who had only a single dose of one or both vaccines, 30
children who had received 2 doses of each vaccine, two
children who received two doses of PCV13, and one
child who had received two or more doses of more than
one PCV. Of 895 children in this analysis, 444 were in
the PCV7 group and 451 in the PHiD-CV10 group. All
had received two or more doses of appropriate vaccine
and not more than one dose of any other PCV. Most
children had received 3 or more PCV doses (Table 2).
Region and communities
All communities were in the tropical Top End region of
Australia. Visits were made each year between early
February and mid-December, the majority being the
between April and December, during the dry and pre-
cyclone season. Mobility is high amongst these families.
We have previously found that around 84% of young
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nity at any one visit [1]. Many additional factors influenced
coverage during the course of this surveillance including
Traditional Owner approvals to access the community,
unscheduled cultural ceremonies such as funerals, parental
consents, weather events, availability of accommodation for
research staff, and the cost of travel. The sampling strategy
thus resulted in differing proportions of children from 25
communities and 7 regions being seen over time (up to
44% age-eligible children were seen each year in the largest
communities). Ten communities contributed at least 10
children to each of the PCV7 and PHiD-CV10 groups; 5 of
these, the largest in each of 5 regions, contributed 59% data
in the PCV7 group and 59% in the PHiD-CV10 group.
Participant characteristics
Age, gestational age, birth weight and gender
The mean ages were 20 mo and 18 mo for PCV7 and
PHiD-CV10 groups, respectively (Difference 2 months
[95% CI 1 to 3] p = 0.0001). Mean gestational age and
mean birth weight were significantly higher for PHiD-
CV10 group. There was no significant difference in gender
(Table 3).
General health
Many children had health problems in addition to their
ear disease. Overall, at least 25% children had a skin
problem, mainly impetigo, round 40% had visible runny
nose, and at least 20% children were diagnosed with
cough. Abnormal haemoglobin (<11 mg/dL) was recorded
for at least 30% children tested. Significantly more chil-
dren in the PHiD-CV10 group had scabies, runny nose, or
cough (12%, 44% and 38%, respectively), compared to the
PCV7 group (4%, 38% and 20%, respectively). Antibiotics,
predominantly beta-lactams, had been prescribed within
5 weeks of clinical assessment for 29% PCV7 children
and 42% PHiD-CV10 children (RD 12% [95% CI 6 to
19] p = 0.0001) (Table 3).
Risk factor questionnaire respondents
Of the 444 children in the PCV7 group, 413 (93%) parents
or carers consented to a structured risk factor question-
naire conducted by interview, whereas 296 (66%) parents
or carers of the 451 children in the PHiD-CV10 group
consented to the interview. Almost all interviewees (~97%
in both groups) were the child’s mother. The mean age,
gender and prevalence of any suppurative OM for these
subgroups (Table 4) closely represent the whole cohort.
Importantly also, the prevalence of any suppurative OM
was not significantly different among PHiD-CV10 chil-
dren whose parents consented to an interview and those
who did not (36% versus 44% RD −8% [95% CI −17 to 2]
p = 0.13, data not shown).Comparison of risk factor prevalence among PCV7 and
PHiD-CV10 subgroups
Total household occupancy was not significantly different
between the PCV groups, however the mean number of
children less than 5 years of age per household was signifi-
cantly lower in the PHiD-CV10 group (Difference −0.3
children [95% CI −0.5 to 0] p = 0.01). Other measures of
household crowding, and child care attendance were not
significantly different between PCV7 and PHiD-CV10
groups. For both vaccine groups, almost all children
(~90%) washed with soap the previous day, around 30%
children had a sibling with a history of CSOM (‘runny
ears’), one third of children spent time around the camp-
fire, and most mothers (~60%) smoked cigarettes. Mean
maternal age was ~25 years, one in 5 mothers completed
year 12 and one in four had a short course certificate as
their highest level of formal education. Very few babies
were never breast fed (~6%) and pacifier use was relatively
uncommon (~20%) (Table 4).
Primary outcome: otitis media, by vaccine group and age
Otitis media
Ninety seven per cent of children in each group had at
least one ear successfully assessed. Four children, all in
the PCV7 group, had a diagnosis based on tympanome-
try alone. In both groups, less than 10% had bilateral
normal middle ears. However, of the ~90% with some
form of OM there were vaccine group differences in
OM severity. A diagnosis of OME was made for 41%
PCV7 children compared to 51% PHiD-CV10 children
(RD 10% [95% CI 3 to 17] p = 0.003). AOMwoP was di-
agnosed for 35% PCV7 children and 25% PHiD-CV10
children (RD −9% [95% CI −15 to −3] p = 0.003). Rates
of AOMwiP were similar, 6% and 5% respectively (RD
−1% [95% CI −4 to 2] p = 0.6), as were rate of CSOM 9%
and 8%, respectively (RD −1% [95% CI −5 to 2] p = 0.4).
Of 401 PCV7 children and 424 PHiD-CV10 children
with bilateral otoscopic assessments, 34% and 45%, re-
spectively had bilateral OME; 6% in each group had uni-
lateral OME (Table 5).
For combination diagnostic categories, the PHiD-CV10
group had significantly less suppurative OM (39% versus
51%, RD −12% [95% CI −19 to −5] p = 0.0004) and similar
rates of TMP (14% versus 17%. RD −3% [95% CI −8 to 2]
p = 0.2) compared to the PCV7 group. Very few mothers
(~6%) reported that their child had had ear pain on the
day or during the night prior to the ear assessment
(Table 5).
Comparisons of OM prevalence between recipients of
non-mixed PCV schedules (353 PCV7- and 319 PHiD-
CV10-recipients) showed almost identical differences in
prevalence of OME (RD = 12% [95% CI 5 to 20] p =
0.001), any suppurative OM (RD = −16% [95% CI −24
to −8] p < 0.0001), and any TMP (RD = −3% [95% CI
Table 3 Participant characteristics, general health and antibiotics prescribed, by vaccination group
PCV7 PHiD-CV1 Absolute difference in
mean or % [95% CI]
P*
N Mean (SD) or% N Mean (SD) or%
Age (mo) 444 20 (8) 451 18 (7) 2 [1-3] 0.0001
0 to <3 0 0
3 to <6 8 2% 9 2%
6 to <9 48 11% 60 13%
9 to <12 39 9% 46 10%
12 to <18 87 20% 118 26%
18 to <24 102 23% 106 24%
24 to <36 160 36% 112 25%
Gestational age (weeks) 378 37.7 (2.8) 426 38.1 (2.3) 0.4 [0 to 0.7] 0.04
Birth weight (kg) 431 2.97 (0.65) 431 3.06 (0.61) 0.09 [0.00 to 0.17] 0.04
Sex (female) 210 47% 230 51% 4% [−3 to 10] 0.27
General health
SKIN assessed 434/444 98% 435/451 96%
Normal 326 75% 303 70% −5% [−11 to 0] 0.07
Scabies 19 4% 53 12% 8% [−4 to 11] <0.0001
Impetigo 62 14% 67 15% 1% [−4 to 6] 0.64
Tinea 19 2% 13 3% 1% [−1 to 3] 0.39
other 20 6% 27 6% 0% [−3 to 3] 0.96
Runny Nose 165/432 38% 198/445 44% 6% [0 to 13] 0.06
Any cough 86/436 20% 169/457 38% 18% [12 to 24] <0.0001
Other
Any antibiotics prescribed in previous 5 weeks 130/444 29% 189/451 42% 12% [6 to 19] 0.0001
Beta-lactam 101/444 23% 158 35% 12% [6-18] 0.0001
Macrolide 14/444 3% 18 4% 1% [−2 to 3] 0.50
Topical 18/426 4% 18/433 4% 0% [−3 to 3] 0.97
Haemoglobin (<11 mg/dL) 122/402 30% 139/403 34% 4% [−2 to 11] 0.21
*Bold signifies P value less than 0.05.
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sons of recipients of at least 2 doses of PCV and not
more than one dose of an alternative PCV (Risk Differ-
ences of 10%, −12% and −3% for OME, any suppurative
OM and any TMP, respectively) (Table 5).
PPV23 was received by 138 children in the PCV7
group. In a post-hoc analysis, we found that compared
to 39 age-eligible children in the PCV7 group who did
not receive PPV23, there was no significant association
between PPV23 and suppurative OM, although TMP
was significantly more common in the PPV23 group
(24%) than the non-PPV23 vaccinated group (8%) (RD
16%, 95% CI 5 to 27] p = 0.03, data not shown).
Age and any suppurative OM
A consistent difference in vaccine group prevalence of
suppurative OM was seen in all age groups up to
24 months of age (Table 6).Univariate and multivariate analyses of risk factors for
any suppurative OM
In a univariate analysis adjusting for community, PHiD-
CV10 compared to PCV7 was significantly negatively
associated with any suppurative OM (Odds Ratio = 0.65
[95% CI 0.5 to 0.9] p = 0.003) (Table 7). Univariate analyses
of other risk factors for any suppurative OM showed
increased risk as the additional number of children under
the age of 5 years per household increased (OR 2.4 [95% CI
1.5 to 4] p = 0.001 for the third child) and reduced risk
as age of the child increased (OR 0.33 [95% CI 0.2 to
0.5] p < 0.0001, for the third year). Females were at
increased risk compared to males (OR 1.4 [95% CI 1.1
to 1.9] p = 0.02). Antibiotic prescribing within 5 weeks
of assessment had no significant impact on prevalence
of any suppurative OM (OR 1.2 [95% CI 0.9 to 1.6] p = 0.2).
There was also no significant association of suppura-
tive OM with abnormal haemoglobin, any child care
Table 4 OM risk factors, by vaccination group
PCV7 PHiD-CV10 Absolute difference in
mean or % [95% CI]
P*
N Mean
(SD) or %
N Mean
(SD) or %
Risk factor questionnaire response
No parents consented 413/444 93% 296/451 66% −27% [−32 to −22] <0.0001
Mother interviewed 400/413 97% 290/296 98% 1% [−1 to 3] 0.36
Characteristics of children in consented subgroups
PCV7 PHiD-CV10
Age (months) 413 20 (8) 296 18(7) 2.0 [0.9 to 3.2] 0.0008
Sex (female) 198 48% 151 51% 3% [−4 to 11] 0.42
Any Suppurative OM 208/395 53% 104/285 36% −16% [−24 to −9] <0.0001
Risk factors
Crowding (persons per household) 402 8.6 (4.5) 290 8.2 (3.9) −0.4 [−1.0 to 0.3] 0.23
Crowding (children < 5 years of age per household) 408 2.4 (1.6) 291 2.1 (1.2) −0.3 [−0.5 to −0.1] 0.01
Crowding Index (%households with > 2 additional
children < 5 years of age)
132/408 32% 75/291 26% −6% [−13 to 0.2] 0.06
Child Care (any attendance > 3 days per week) 51/409 12% 41/295 14% 1.4% [−4 to 7] 0.58
Child Care (days/week) 408 0.68 (1.7) 295 0.77 (1.7) 0.09 [−0.34 to 0.16] 0.49
Washed with soap yesterday 327/362 90% 258/293 88% −2% [−7 to 3] 0.35
Any sibling with history of “runny ears” 101/370 27% 80/249 32% 5% [−3 to 12] 0.20
Child near campfire last week 134/402 34% 88/287 31% −3% [−10 to 4] 0.46
Maternal smoking 233/410 57% 178/283 61% 4% [−3 to 11] 0.29
Maternal age at birth of this child 297 25 (5.4) 244 26 (6.4) 1 [0.1 to 2] 0.04
Maternal education (certificate) 105/382 27% 60/247 24% −3% [−10 to 4] 0.37
Never breast fed 28/409 7% 14/296 5% −2% [−6 to 1] 0.23
Pacifier (ever) 78/404 19% 52/296 18% −2% [−8 to 4] 0.56
*Bold signifies P value less than 0.05.
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maternal smoking, being near a camp fire, maternal
age or education, breast feeding, pacifier use, or gesta-
tional age less than 32 weeks (Table 7).
A random-effects logistic regression model (with adjust-
ment for inconsistent community representation) was
conducted with complete data from 465 children without
suppurative OM and 383 with suppurative OM. We found
that compared to vaccination with PCV7, PHiD-CV10
vaccination was associated with less suppurative OM
(Odds Ratio, OR = 0.6 [95% CI 0.4 to 0.8] p = 0.001) as
was age (OR 0.3 [95% CI 0.2 to 0.5] p < 0.0001 for the
third year). Living with more than 3 other children
under 5 years of age (OR = 2.4 [95% CI 1.4 to 4.0]
p = 0.001) and female gender (OR 1.5 [95% CI 1.1 to
1.9] p = 0.02) were also associated with increased sup-
purative OM. Recent antibiotic prescribing was not as-
sociated with increased or decreased rates of
suppurative OM (Table 7).Discussion
Our surveillance highlights the poor general health,
particularly poor ear health, of Australian Indigenous
children living in remote communities during the PCV
era. Although the children we assessed were generally
not considered unwell by their careers and were not
presenting for ear health services, nine of every ten
children in each vaccine group had some form of OM.
Most of these children had forms of OM that required
medical and/or audiological referral and possibly oto-
laryngologist review. In addition, one in four or five
children had skin problems, more than one third had
runny nose and just under one third had a cough. Antibi-
otics had been recently prescribed for more than one in
four children. Although few children under the age of
6 months were seen, the early age of OM onset remains a
huge challenge and requires new strategies for prevention.
Our comparison found a 12% absolute reduction in any
suppurative OM (either AOMwoP, AOMwiP or CSOM)
Table 5 Prevalence of all forms of otitis media including combination categories, by vaccination groups
PCV7 444 PHiD-CV10 451 Absolute risk
difference [95%CI]
P value
n % n %
No. children without assessment 12 3% 14 3%
No. children with diagnosis based on tympanometry alone 4 1% 0 0%
No. children with unilateral otoscopy 27 6% 13 3%
No. children with bilateral otoscopy 401 90% 424 94%
No. children with at least one ear successfully assessed 432 97% 437 97%
Clinical diagnosis PCV7 432 PHiD-CV10 437
normal 32 7% 41 9% 2% [−1 to 6] 0.29
OME 175 41% 222 51% 10% [3-17] 0.002
AOMwoP 150 35% 111 25% −9% [−15 to −3] 0.003
AOMwiP 27 6% 24 5% −1% [−4 to 2] 0.63
Dry Perforation 8 2% 5 1% −0.7% [−2 to 1] 0.39
CSOM 40 9% 34 8% −1% [−5 to 2] 0.43
Bilateral OME* 136/401 34% 191/424 45% 11% [4-17] 0.001
Unilateral OME* 24/401 6% 25/424 6% 0.1% [−3 to 3] 1.000
Combination OM categories
Any suppurative OM (AOMwoP, AOMwiP, CSOM) 217 51% 169 39% −12% [−19 to −5] 0.0004
Any TMP (AOMwiP, DP, CSOM) 75 17% 63 14% −3% [−8 to 2] 0.24
Any ear pain (today or last night) 34/408 8% 17/337 5% −3% [−7 to 0.2] 0.08
Non-mixed PCV schedules PCV7-only 353** PHiD-CV10-only 319
No. children with at least one ear successfully assessed 345 98% 309 97%
Normal 24 7% 31 10% 3% [−1 to 7] 0.16
OME 127 37% 152 49% 12% [5 to 20] 0.001
Any suppurative OM (AOMwoP, AOMwiP, CSOM) 191 56% 121 40% −16% [−24 to −8] <0.0001
Any TMP (AOMwiP, DP, CSOM) 62 18% 48 16% −2% [−8 to 3] 0.40
*Laterality of OME could only be determined where bilateral assessments were successful; 401 PCV7 children and 424 PHiD-CV10 children had
bilateral assessments.
**138 children in the PCV7-only group had also received PPV23.
Table 6 Prevalence of any suppurative OM in each age group, by vaccination group
PCV7 424* PHiD-CV10 432* Absolute risk
difference [95%CI]
P
valueAge group n % n %
3 to <6 4/8 50% 3/9 33% −17% [−63 to 30] 0.48
6 to <9 34/47 71% 33/60 55% −16% [−34 to 2] 0.09
9 to <12 27/38 71% 21/45 47% −24% [−45 to −4] 0.03
12 to <18 50/84 59% 46/114 40% −19% [−33 to −5] 0.008
18 to <24 54/98 55% 39/101 39% −16% [−30 to −3] 0.02
24 to <36 48/148 32% 27/103 26% −6% [−18 to 5] 0.29
*Denominator: Dry perforation (8 children in the PCV7 group and 5 children in the PHiD-CV10 group) have been excluded.
Any suppurative OM any AOMwoP (Acute Otitis Media without Perforation), any AOMwiP (Acute Otitis Media with Perforation), or any CSOM (Chronic Suppurative
Otitis Media).
CI, Confidence Interval.
PCV7, 7-valent pneumococcal conjugate vaccine.
PHiD-CV10, 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine.
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Table 7 Univariate and multivariate analyses of risk factors for suppurative OM, adjusted for community
With suppurative OM** UNI-VARIATE OR 95% CI p MULTI-VARIATE OR 95% CI P*
Vaccine group
PCV7 51%
PHiD-CV10 39% 0.64 0.48 to 0.86 0.003 0.58 0.41 to 0.80 0.001
Children under age of
5 years in household
0 39% 0.003 0.009
1 47% 1.43 0.98 to 2.10 1.34 0.91 to 1.98
2 53% 1.85 1.12 to 3.07 1.66 0.99 to 2.80
3+ 60% 2.42 1.46 to 3.99 2.36 1.41 to 4.00
Age group (years)
< 1 year 58% 0.000 0.000
1 to < 2 years 47% 0.70 0.49 to 1.0 0.72 0.50 to 1.04
2 to < 3 years 30% 0.33 0.22 to 0.49 0.31 0.20 to 0.47
Gender
Male 41%
Female 49% 1.41 1.07 to 1.86 0.016 1.46 1.07 to 1.92 0.016
Antibiotics prescribed
in previous 5 weeks
None 44%
Any 47% 1.21 0.90 to 1.62 0.20 1.24 0.91 to 1.69 0.17
Haemoglobin
> = 11 mg/dL 42%
<11 mg/dL 49% 1.28 0.93 to 1.75 0.13
Child care attendance
none 47%
any 47% 1.03 0.64 to 1.67 0.91
Sibling history of OM “runny ears’
No 47%
Yes 47% 0.98 0.69 to 1.39 0.90
Maternal smoking
No 46%
Yes 48% 1.11 0.80 to 1.53 0.53
Child near campfire last week
No 48%
Yes 47% 0.89 0.63 to 1.35 0.51
Maternal age at birth of this child
> = 21 yrs 43%
< 21 yrs 52% 1.39 0.97 to 1.99 0.07
Maternal education
no certificate 46%
certificate 49% 1.07 0.74 to 1.57 0.71
Breastfed
Never 51%
Some 47% 0.86 0.45 to 1.65 0.65
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Table 7 Univariate and multivariate analyses of risk factors for suppurative OM, adjusted for community (Continued)
Pacifier
Never 47%
Some 47% 1.02 0.70 to 1.54 0.91
Gestational age
> = 32 weeks 45%
< 32 weeks 54% 1.3 0.60 to 3.06 0.51
*Bold signifies P value less than 0.05.
**Analysis of 383 children with and 465 children without suppurative OM.
Leach et al. BMC Pediatrics 2014, 14:200 Page 9 of 11
http://www.biomedcentral.com/1471-2431/14/200including a small non-significant 3% reduction in any
TMP (AOMwip, DP or CSOM), and a concomitant 10%
increase in OME, in the PHiD-CV10 group compared
to the PCV7 group. Importantly the difference in any
suppurative OM was present from an early age, reaching
statistical significance after 9 months of age.
Implications of this shift from suppurative to non-
suppurative disease could reduce rates of antibiotic
prescribing and change demand for surgical procedures
such as tympanoplasty and tympanostomy tubes.
These improvements in ear health occurred whilst preva-
lence of skin, cough and runny nose increased, suggesting
that there was no strong temporal trend toward improved
child health that might explain the improvement in ear
health.
Sampling was reliant on community approval which
varied each year of surveillance. We previously identified
considerable community variation in prevalence of CSOM
[1]. In an analysis restricted to the data from those com-
munities that were sampled in both eras (data not show),
there were similar differences in AOMwoP and any
suppurative OM, and a significant increase in OME for
the PHiD-CV10 group compared to the PCV7 group.
Furthermore, the adjustment for inconsistent community
representation (using xtset in Stata) did not change the in-
dependent association between vaccine and severity of OM.
We did not use random selection of participants, but
aimed to assess all eligible children in the community. It
is possible that this would bias selection for children
with healthy ears if families of children with poor ear
health refused participation, or bias towards selection of
unhealthy ears if families thought the assessment might
be beneficial. Whether such bias existed in our study,
or whether bias, if it existed, shifted between the two
vaccine era periods was not determined.
Eighty nine children in the PCV7 group had also re-
ceived a single dose of PHiD-CV10, and 40 children in
the PHiD-CV10 group had also received a single dose
of PCV7. Ninety children in the PHiD-CV10 group and
2 in the PCV7 group also received a single dose of
PCV13. Comparisons of OM prevalence between recipients
of non-mixed PCV schedules showed very similar differ-
ences in prevalence between PCV groups, which supports ahypothesis that an additional single dose of an alternative
PCV vaccine may have no detectable impact on clinical
outcome. We have not presented a comprehensive separate
analysis of the impact of a booster PPV23 dose. There was
no significant association between PPV23 and suppurative
OM although significantly more PPV23-vaccinated children
had TMP (data not shown).
Our comparison of risk factors was potentially compro-
mised by the large number of carers in the PHiD-CV10
group who refused consent for the risk factor question-
naire. Nonetheless, the ear health of PHiD-CV10 children
for whom we did not get consent for the questionnaire
was similar to that of PHiD-CV10 children for whom we
did have consent, so we consider the consent refusal to be
unrelated to ear health.
Household crowding [12] and child care attendance
[13,14] are known to be associated with increased risk
of OM. The PHiD-CV10 group had a lower mean
household number of children under the age of 5 years
compared to the PCV7 group and significantly greater
exposure to recent beta-lactam antibiotics. The antibi-
otics prescribed could be either protective [15-17], or
indicative of a recent OM episode. The multivariate
analysis of risk factors for suppurative OM confirmed
that recent antibiotic prescribing was neither a signifi-
cant risk nor protective factor for suppurative OM.
Thus, three key factors have been found to be associated
with the reduction in suppurative OM and concomitant
increase in OME; i) PHiD-CV10 was protective compared
to PCV7, ii) living in a household with more children less
than 5 years of age per household was a significant risk
factor, and iii) older age is protective of suppurative OM.
Recent prescribing of antibiotics, child care attendance
and other measured factors were not associated with
suppurative OM.
Our data must be interpreted with caution since most
(70%) children vaccinated with PCV7 were seen between
2009 and 2010 whereas most (87%) PHiD-CV10 children
were seen between 2011 and 2012. Factors not measured
may also have changed during this period. In addition,
PHiD-CV10 has recently been shown to have no impact
on nasopharyngeal (NP) carriage of non-typeable H.
influenzae [18]. Whilst we understand the NP to be the
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is feasible that vaccine induced immune responses can
deliver protection in the middle ear without reducing
NP carriage. This hypothesis is plausible (not all NP
colonised children have OM), and should be confirmed
in randomised controlled vaccine trials with OM out-
comes and concomitant studies of NP microbiology.
Conclusion
Our study identifies ongoing high rates of ear disease
and other infections in Indigenous children living in
remote regions. A comparison of ear health of children
receiving PCV7 or PHiD-CV10 according to the NT
childhood vaccination schedules shows that PHiD-CV10
was associated with a 12% reduction in suppurative ear
disease (AOM without perforation, AOM with perforation
and CSOM combined) and a concomitant increase in
OME. Multivariate logistic regression did not change
these findings. Clinical trials of vaccines that offer broader
coverage of OM pathogens and that are effective from an
earlier age are urgently needed in this highly disadvan-
taged population.
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